• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Longeveron Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/16/25 4:01:25 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    false 0001721484 0001721484 2025-06-13 2025-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 13, 2025

     

    Longeveron Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40060   47-2174146
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    1951 NW 7th Avenue, Suite 520, Miami, Florida 33136

    (Address of Principal Executive Offices)

     

    Registrant’s Telephone Number, Including Area Code: (305) 909-0840

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Common Stock, $0.001 par value per share   LGVN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

     

    Emerging Growth Company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    (a) The Company’s annual meeting of stockholders was held on June 13, 2025.

     

    (b) Three (3) proposals were submitted by the Company’s Board of Directors (the “Board”) to a vote of the Company’s stockholders, and the final results of the voting on each proposal, rounded to the nearest whole share, are noted below.

     

    The Company’s stockholders elected the Board’s Class I director nominee, Rock Soffer, for a three-year term expiring at the 2028 annual meeting of stockholders, or until his successor is duly elected and qualified as a director or his earlier resignation, disqualification, disability or removal; approved an amendment to the Second Amended and Restated Longeveron Inc. 2021 Incentive Award Plan (as amended, the “Plan”) to increase the number of shares authorized by the Plan and make commensurate changes; and ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for fiscal 2025.

     

    A copy of the Plan is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Proposal No. 1- Director Election

     

    Nominee   For   Withheld   Broker Non Vote
    Rock Soffer   8,721,836   356,027   5,459,478

      

    Proposal No. 2 – Approval of an amendment to the Second Amended and Restated Longeveron Inc. 2021 Incentive Award Plan 

     

    For   Against   Abstain   Broker Non Vote
    8,626,417   425,061   26,385   5,459,478

      

    Proposal No. 3 - Ratification of the Appointment of Independent Registered Public Accounting Firm for Fiscal 2025 

     

    For   Against   Abstain   Broker Non Vote
    13,967,643   182,971   386,728   0

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description
    10.1   Third Amended and Restated Longeveron Inc. 2021 Incentive Award Plan (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement filed with the SEC on April 28, 2025).
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      LONGEVERON INC.
       
    Date: June 16, 2025 /s/ Wa’el Hashad
      Name:  Wa’el Hashad
      Title:  Chief Executive Officer

     

     

    2

     

     

     

    Get the next $LGVN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Hare Joshua

      4 - Longeveron Inc. (0001721484) (Issuer)

      7/17/25 7:47:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Soffer Rock was granted 17,000 shares, increasing direct ownership by 8% to 226,034 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      7/17/25 7:46:33 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agafonova Nataliya was granted 102,000 shares, increasing direct ownership by 75% to 238,697 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      7/17/25 7:46:16 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Longeveron® Appoints Than Powell as Chief Business Officer

      Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

      6/26/25 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

      MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

      11/11/24 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neha Motwani Elected to Longeveron® Board of Directors

      MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte

      7/9/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:29 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hashad Mohamed Wa'El Ahmed bought $24,999 worth of shares (10,638 units at $2.35), increasing direct ownership by 118% to 19,616 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soffer Rock bought $325,000 worth of shares (138,298 units at $2.35), increasing direct ownership by 197% to 208,534 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    SEC Filings

    See more
    • Longeveron Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Longeveron Inc. (0001721484) (Filer)

      7/9/25 4:01:48 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Longeveron Inc.

      S-8 - Longeveron Inc. (0001721484) (Filer)

      6/20/25 4:25:28 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Longeveron Inc. (0001721484) (Filer)

      6/16/25 4:01:25 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

      Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells" from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)New technology substantially advances Longeveron's repertoire of stem cell therapy technologiesOpportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWIRE) --  Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that i

      7/21/25 9:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

      Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000 children worldwideEffective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis MIAMI, July 08, 2025 (GLOBE NEWSWIRE) --  Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has ap

      7/8/25 9:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Appoints Than Powell as Chief Business Officer

      Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

      6/26/25 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Longeveron with a new price target

      ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

      12/6/24 7:54:21 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EF Hutton initiated coverage on Longeveron with a new price target

      EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

      1/5/22 10:22:40 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Financials

    Live finance-specific insights

    See more
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

      5/2/25 8:30:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue

      2/28/25 4:04:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

      SC 13G/A - Longeveron Inc. (0001721484) (Subject)

      11/14/24 4:20:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      7/26/24 4:18:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      4/17/24 4:03:33 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care